Home / Stocks / Orchid Pharma Limited
ORCHPHARMA

Orchid Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹948.6

Change

-7.35 (-0.77%)

Open

₹962.5

Prev. Close

₹955.95

Day High

₹962.5

Day Low

₹927.8

Volume Analysis

Traded

111,186

Delivered

27,521

Delivery %

24.75%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (2)

  • •Low return on equity (1.49%)
  • •Low operating margin (4.1%)

Opportunities (1)

  • •Strong 3-year revenue growth (22.8%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹999.5 ₹981.0 ₹964.8 ₹946.3 ₹930.1 ₹911.6 ₹895.4
Fibonacci ₹981.0 ₹967.74 ₹959.56 ₹946.3 ₹933.04 ₹924.86 ₹911.6
Camarilla ₹958.14 ₹954.96 ₹951.78 ₹946.3 ₹945.42 ₹942.24 ₹939.06

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+19.6%

1 Week

+10.59%

1 Month

+6.96%

3 Months

-5.33%

6 Months

+34.27%

1 Year

+9.07%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

1.18%

Net margin 1.03% × asset turnover 0.77x × equity multiplier 1.49x

Company Overview

Sector

Healthcare

Market Cap

₹5,296 Cr

P/E (TTM)

293.0

ROE

1.49%

Book Value

₹300.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Orchid Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (100/100), while Business Quality (26/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (1.49%); low operating margin (4.1%). FII holding has been falling.

TopFund Score — Fundamentals Quality

52/100 — Average

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

66

Valuation

33

Cash Flow

39

Corporate Governance

66

Momentum

61

Institutional Ownership

43

Business Quality

26

Risk & Volatility

42

Liquidity

30

From Screener.in

  • +Promoter holding has increased by 4.61% over last quarter.
  • −Stock is trading at 2.95 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Tax rate seems low
  • −Company has a low return on equity of 6.76% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

QIP monitoring report for Sept 2026 shows no deviation; Jammu facility commercial operations now expected by February 2027.

Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026

Orchid Pharma signs Latin America licensing and supply deal for Exblifep across nine markets; potential USD 80 million.

Board approved enabling resolution on Oct. 20, 2026 to raise up to Rs 600 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 183 199 221 217 244 223 217 237 263 194 207 368 304
Expenses + 161 175 185 188 212 192 191 209 269 195 206 338 290
Operating Profit 22 23 35 29 32 30 26 28 -6 -1 2 30 14
OPM % 12.1% 11.72% 16.04% 13.32% 13.29% 13.62% 12.13% 11.79% -2.15% -0.76% 0.75% 8.19% 4.6%
Other Income + 2 8 8 13 8 8 8 4 12 11 -2 8 2
Interest 6 4 4 3 4 3 4 4 2 4 3 2 2
Depreciation 8 8 9 8 8 9 9 9 11 9 9 11 11
Profit before tax 11 20 30 30 28 26 22 19 -7 -3 -12 25 3
Tax % 0.0% 0.0% 0.0% -10.27% -0.53% 0.0% 0.0% -0.21% 0.0% 0.0% 0.0% 0.0% 2.64%
Net Profit + 9 20 29 33 29 27 21 22 -6 -6 -13 26 3
EPS in Rs 2 4 6 7 6 5 4 4 -1 -1 -2 5 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 40 20 38 3 34 12 -1 9 8 -13 -5 55 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 18m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,747 873 797 683 600 484 450 560 666 819 1,398 1,233 1,073
Expenses + 1,429 703 794 659 612 515 421 505 581 708 1,247 1,185 1,029
Operating Profit 317 171 3 24 -12 -31 29 55 84 111 151 48 44
OPM % 18.0% 20.0% 0.4% 3.6% -2.0% -6.0% 7.0% 10.0% 13.0% 14.0% 11.0% 3.9% 4.1%
Other Income + 156 -28 -59 20 218 24 15 67 52 31 26 15 19
Interest 537 294 347 310 7 6 52 33 33 17 13 9 11
Depreciation 325 145 141 133 130 118 109 87 55 33 42 43 40
Profit before tax -389 -296 -544 -399 69 -131 -117 2 48 92 122 10 12
Tax % -49.0% -6.0% -9.0% -12.0% 0.0% 0.0% 0.0% 0.0% 0.0% -3.0% -8.0% -2.0% —
Net Profit + -197 -279 -495 -353 69 -131 -117 -2 46 92 135 10 11
EPS in Rs -23 -31 -56 -40 8 -32 -29 0 11 18 27 2 2
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -10 -50 -9 -14 -12 -19 -7 24 19 23 71 -12 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 244 -40 -556 -881 -793 725 612 607 648 1,119 1,494 1,504
Borrowings + 3,211 3,215 3,106 3,202 3,230 566 453 268 331 135 154 307
Other Liabilities + 521 598 616 715 551 128 132 195 205 249 414 432
Total Liabilities 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 2,077 2,258
Fixed Assets + 1,795 1,637 1,497 1,386 1,256 858 670 584 573 620 708 692
CWIP 282 280 288 272 278 26 7 10 46 31 81 414
Investments 1 1 1 1 0 0 15 45 44 46 60 67
Other Assets + 1,984 1,944 1,470 1,467 1,542 576 544 472 561 857 1,229 1,086
Total Assets 4,061 3,862 3,256 3,125 3,077 1,460 1,237 1,111 1,225 1,554 2,077 2,258
Equity Capital 85 89 89 89 89 41 41 41 41 51 15 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -369 212 401 9 12 81 24 92 18 126 51 126
Cash from Investing Activity + 1,334 -1 -176 -28 45 167 67 113 -31 -312 -36 -277
Cash from Financing Activity + -597 -286 -465 33 0 -250 -165 -217 31 167 2 137
Net Cash Flow 367 -76 -240 15 57 -2 -74 -11 18 -19 17 -14
Free Cash Flow 965 211 392 3 5 77 23 238 -8 61 -102 -255
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -102 124 13,628 67 -138 -226 63 173 22 113 44 259

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.84% → 74.45%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.52% 10.47% 9.82% 9.94% 8.63% 7.37% 9.34% 9.57% 9.61% 9.04% 8.62% 7.17%
Promoters 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 74.45%
FII 4.14% 1.96% 1.42% 1.94% 2.53% 2.69% 1.39% 1.56% 1.17% 0.87% 0.8% 0.93%
DII 14.51% 17.73% 18.93% 18.3% 19.0% 20.1% 19.43% 19.04% 19.38% 20.24% 20.75% 17.44%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Orchid Pharma Limited (this stock) 5,296 293.0 2.95 1.49%
Artemis Med Service Ltd 5,415 46.2 5.47 12.0%
Sahajanand Medical Tech L 5,427 75.6 — 10.4%
Senores Pharmaceuticals L 5,125 38.4 5.11 13.4%
Morepen Lab. Ltd 5,061 26.8 3.67 5.33%
Iol Chem And Pharma Ltd 5,587 26.4 2.91 8.41%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%

Which Mutual Funds Hold Orchid Pharma Limited?

Frequently Asked Questions about Orchid Pharma Limited

Community Sentiment

What are other investors saying about Orchid Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.